Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 27877


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Acne
  • Personal Care Products
  • Delivery
  • Dermatology
  • Skin care

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27877

License Grant
The Licensee acquired an exclusive license from the University to the patent covering the commercialization of botulinum in the treatment of acne.
License Property
The Licensor has developed a patent using botulinum in the treatment of acne.

Patent No. 7,226,605, “Botulinum toxin in the treatment and prevention of acne”

Field of Use
The Licensor will seek to commercialize products for the treatment of Acne.

IPSCIO Record ID: 28984

License Grant
The Licensee acquired from the University an exclusive License to various intellectual property rights upon which the Licensee's proprietary NDS formulation technology is based. The License is an exclusive, worldwide, royalty-bearing License with the right to grant subLicenses.
License Property
NDS technolgy aids in the delivery of large molecules through small gaps between skin cells.

NDS formulation technology enables the transdermal delivery of large molecules, such as botulinum by coating the botulinum with a proprietary formulation of excipients, or therapeutically inactive ingredients. The NDS coating thereby enables the molecules to enter into the small naturally-occurring gaps between skin cells.

Field of Use
These formulations will aid in the treatment of hyperhidrosis (excessive sweating), facial wrinkles, and other FDA-approved clinical indications for injectable botulinum, as well as new potential clinical indications such as acne.

IPSCIO Record ID: 377000

License Grant
This Agreement is for the purchase of Accutane with a term of 10 years. The agreement contains customary representations, warranties, and indemnities.
License Property
Accutane® is an oral isotretinoin drug for the treatment of severe recalcitrant acne. Accutane® (isotretinoin 20mg, 30mg, and 40mg capsules USP) is indicated for treating severe recalcitrant nodular acne. Accutane is used to treat a type of severe recalcitrant nodular acne that has not been helped by other treatments, including antibiotics. Severe recalcitrant nodular acne occurs when many red, swollen, tender lumps form in the skin. Patients with severe nodular acne are at higher risk of scarring. Accutane belongs to a class of drugs that affects all four major pathogenic processes in acne increased sebum production, irregular follicular desquamation, propionibacterium acnes proliferation and inflammation. Accutane has achieved a strong market position and is well known in the dermatology community.
Field of Use
Field of use is for the treatment of recalcitrant nodular acne.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.